News

ARYx‘s loss from operations was $2.15m, compared to $7.63m for the comparable period in 2009. For the nine months ended 30 September 2010 ARYx posted a net loss

According to AP Pharma, the net loss was higher in the current fiscal quarter primarily due to $1m of income recognised in the prior year quarter in connection

Zyngenia is a privately held biotherapeutics company focused on the development of next-generation multi-specific antibody-based therapeutics. Selexis co-founder and CEO Igor Fisch said that they are excited to

Pro-Pharmaceuticals’ operating loss was $1.21m, compared to $1.25m for the comparable period in 2009. For the nine months ended 30 September 2010 Pro-Pharmaceuticals posted a net loss of

According to Inovio Pharmaceuticals, the decrease in the respective periods were mainly due to no revenue being recognised under the terminated Wyeth collaboration and licensing agreement as a

In a 24-week, placebo-controlled, monotherapy study of the impact of Cycloset on glycemic control in 159 overweight adults (BMI = 26.0kg/m2 for males and = 28.0kg/m2 for females)

China Shenghuo Pharmaceutical is a specialty pharmaceutical company that focuses on the manufacture, research, development and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products. China

ICON said that with this alliance it is strengthening its current biomarker solution to include an integrated suite of labeling, separation and mass spectrometry technologies for protein and

Dalton supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. The company provides